Bupivacaine HClAnaesthetic drug CAS# 18010-40-7 |
- Amiloride HCl dihydrate
Catalog No.:BCC5068
CAS No.:17440-83-4
- Procaine HCl
Catalog No.:BCC5072
CAS No.:51-05-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 18010-40-7 | SDF | Download SDF |
| PubChem ID | 64737 | Appearance | Powder |
| Formula | C18H29ClN2O | M.Wt | 324.89 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO > 10 mM | ||
| Chemical Name | 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide;hydrochloride | ||
| SMILES | [H+].[Cl-].CCCCN1CCCCC1C(=O)Nc2c(C)cccc2C | ||
| Standard InChIKey | SIEYLFHKZGLBNX-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C18H28N2O.ClH/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3;/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21);1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Bupivacaine HCl Dilution Calculator
Bupivacaine HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.078 mL | 15.3898 mL | 30.7796 mL | 61.5593 mL | 76.9491 mL |
| 5 mM | 0.6156 mL | 3.078 mL | 6.1559 mL | 12.3119 mL | 15.3898 mL |
| 10 mM | 0.3078 mL | 1.539 mL | 3.078 mL | 6.1559 mL | 7.6949 mL |
| 50 mM | 0.0616 mL | 0.3078 mL | 0.6156 mL | 1.2312 mL | 1.539 mL |
| 100 mM | 0.0308 mL | 0.1539 mL | 0.3078 mL | 0.6156 mL | 0.7695 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Bupivacaine Hydrochloride is a local anaesthetic drug belonging to the amino amide group.Bupivacaine hydrochloride is an effective local anesthetic agent. It has a rapid onset time, a high frequency of surgical anesthesia, a long duration, and a low incid
- SB 224289 hydrochloride
Catalog No.:BCC6976
CAS No.:180084-26-8
- Voafinidine
Catalog No.:BCN6738
CAS No.:180059-77-2
- SDZ NKT 343
Catalog No.:BCC7349
CAS No.:180046-99-5
- Ketohakonanol
Catalog No.:BCN7427
CAS No.:18004-20-1
- 7-Chlorokynurenic acid
Catalog No.:BCC6577
CAS No.:18000-24-3
- 3-oxo-Olean-12-en-28-oic acid
Catalog No.:BCN3171
CAS No.:17990-42-0
- 27-Hydroxymangiferolic acid
Catalog No.:BCN4689
CAS No.:17983-82-3
- Aflastatin A
Catalog No.:BCN1822
CAS No.:179729-59-0
- N-Benzoyl-leucine
Catalog No.:BCC9092
CAS No.:17966-67-5
- Macrocarpal J
Catalog No.:BCN1139
CAS No.:179603-47-5
- Amabiline
Catalog No.:BCN1950
CAS No.:17958-43-9
- Cynaustine
Catalog No.:BCN1951
CAS No.:17958-39-3
- Quercetin 3-O-glucoside-7-O-rhamnoside
Catalog No.:BCN1520
CAS No.:18016-58-5
- Megastigm-7-ene-3,4,6,9-tetrol
Catalog No.:BCN6511
CAS No.:180164-14-1
- Anthracophyllone
Catalog No.:BCN7606
CAS No.:1801750-22-0
- Ganoderlactone D
Catalog No.:BCN7849
CAS No.:1801934-15-5
- Phytolaccagenin
Catalog No.:BCN1140
CAS No.:1802-12-6
- NCT-501
Catalog No.:BCC6539
CAS No.:1802088-50-1
- Cyclo(Leu-Ala)
Catalog No.:BCN2428
CAS No.:1803-60-7
- Perillaldehyde
Catalog No.:BCN8294
CAS No.:18031-40-8
- Solifenacin hydrochloride
Catalog No.:BCC5193
CAS No.:180468-39-7
- Fmoc-D-Asn(Trt)-OH
Catalog No.:BCC3084
CAS No.:180570-71-2
- Gentioflavin
Catalog No.:BCN3619
CAS No.:18058-50-9
- Peiminine
Catalog No.:BCN1095
CAS No.:18059-10-4
Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting.[Pubmed:22900785]
Curr Med Res Opin. 2012 Oct;28(10):1609-15.
OBJECTIVE: Assess comparative efficacy of liposome bupivacaine administered at doses Bupivacaine HCl administered at doses Bupivacaine HCl) controlled multimodal analgesia studies using a single dose of liposome bupivacaine or comparator, given via administration into the surgical site before end of surgery (i.e., inguinal hernia repair, total knee arthroplasty, hemorrhoidectomy, breast augmentation, or bunionectomy). Data from study arms that received liposome bupivacaine doses Bupivacaine HCl (329, p = 0.039). Median time from administration of study drug to first use of opioid rescue medication was significantly longer for liposome bupivacaine (10 h vs 3 h, p < 0.0001). Liposome bupivacaine was associated with a significant reduction in opioid use (12 mg vs 19 mg; p < 0.0001) and incidence of ORAEs (20% vs 36%; p < 0.0001), compared with Bupivacaine HCl. CONCLUSIONS: In this pooled analysis from nine studies representing five different surgical procedures, liposome bupivacaine administered at doses Bupivacaine HCl.
Time to Analgesia Onset and Pharmacokinetics After Separate and Combined Administration of Liposome Bupivacaine and Bupivacaine HCl: Considerations for Clinicians.[Pubmed:27347237]
Open Orthop J. 2016 Apr 12;10:94-104.
BACKGROUND: Liposome bupivacaine is a prolonged-release bupivacaine formulation indicated for single-dose administration into the surgical site to produce postsurgical analgesia. METHODS: An overview of time to onset of analgesia observed with liposome bupivacaine in human studies is provided, as well as a summary of data from pharmacokinetic studies including those that assessed pharmacokinetics after separate versus coadministration of liposome bupivacaine and Bupivacaine HCl. RESULTS: Data from multiple studies show that local administration of liposome bupivacaine is associated with rapid onset and effective analgesia after surgery. However, the efficacy profile observed in controlled settings may not replicate the profile observed in clinical practice; time to onset may be impacted by nonpharmacologic factors, such as amount of drug given, location and relative vascularity, and variances in surgical techniques. Some clinicians coadminister or admix Bupivacaine HCl and liposome bupivacaine based on the supposition that adjuvant use will result in more rapid onset of efficacy. To date, no clinical studies have been conducted comparing pain-related outcomes following coadministration versus liposome bupivacaine alone. Preclinical pharmacokinetic studies have assessed the potential impact of combined use, which resulted in predictable, additive systemic exposure without compromising the prolonged-release profile of liposome bupivacaine, and without signs of toxicity. CONCLUSION: Based on available data and approved package insert, in the setting of wound infiltration, clinicians have the flexibility to administer liposome bupivacaine alone, coadminister separately with Bupivacaine HCl, or admix with Bupivacaine HCl prior to injection, providing the Bupivacaine HCl dose does not exceed 50% of the liposome bupivacaine dose.
Addition of Liposome Bupivacaine to Bupivacaine HCl Versus Bupivacaine HCl Alone for Interscalene Brachial Plexus Block in Patients Having Major Shoulder Surgery.[Pubmed:28157791]
Reg Anesth Pain Med. 2017 May/Jun;42(3):334-341.
BACKGROUND AND OBJECTIVES: We examined whether liposome bupivacaine (Exparel) given in the interscalene brachial plexus block lowers pain in the setting of multimodal postoperative pain management for major shoulder surgery. METHODS: Fifty-two adult patients were randomized to receive either 5 mL of 0.25% Bupivacaine HCl immediately followed by 10 mL of liposome bupivacaine 133 mg (n = 26) or 15 mL of 0.25% standard bupivacaine alone (n = 26) in interscalene brachial plexus block. The primary outcome (worst pain in the first postoperative week) was assessed by the Modified Brief Pain Inventory short form. Secondary outcomes were overall satisfaction with analgesia (OBAS), functionality of the surgical arm, sleep duration, time to first opioid (tramadol) request and opioid consumption (mEq), sensory-motor block characteristics, and the occurrence of adverse effects. RESULTS: Worst pain was lower in patients given liposome bupivacaine added to standard bupivacaine than in patients given standard bupivacaine alone (generalized estimating equation [GEE] estimated marginal mean values, 3.6 +/- 0.3 vs 5.3 +/- 0.4 points on the Numeric Rating Scale, respectively, although the effect was modest, 1.6 +/- 0.5; 95% confidence interval, 0.8-2.5). Total OBAS scores indicated greater satisfaction (GEE estimated marginal mean values, 1.8 +/- 0.3 vs 3.3 +/- 0.4 on total OBAS, respectively, with modest effect, difference, 1.4 +/- 0.5; 95% confidence interval, 0.5-2.4). There were no differences in any of the other secondary outcomes. CONCLUSIONS: Liposome bupivacaine added to standard bupivacaine may lower pain and enhance patient's satisfaction in the first postoperative week even in the setting of multimodal analgesia for major shoulder surgery.This study was registered with clinicaltrials.gov (NCT02554357) on July 11, 2015, by Principal Investigator Catherine Vandepitte, MD.
Treatment of complex regional pain syndrome with stellate ganglion local anesthetic blockade: a case report of one patient's experiences with traditional bupivacaine HCl and liposome bupivacaine.[Pubmed:27648263]
Clin Case Rep. 2016 Jul 27;4(9):861-5.
Complex regional pain syndrome (CRPS) is a poorly understood, debilitating disorder characterized by severe chronic pain in an affected limb or region of the body. This case presentation is the first to describe the effectiveness and prolonged duration of the effect of liposome bupivacaine in stellate ganglion block for CRPS.
